Welcome to our dedicated page for Artiva Biotherapeutics SEC filings (Ticker: ARTV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Artiva Biotherapeutics filings document its clinical-stage biotechnology business, Nasdaq-listed common stock and material-event reporting. Recent Form 8-K disclosures cover quarterly and annual financial results, Regulation FD updates on AlloNK® (AB-101) clinical data, and exhibits such as press releases and corporate presentations.
The filing record also describes governance and compensation matters, including board and officer appointments, employment arrangements, non-employee director compensation, inducement awards and an option-for-RSU exchange under the 2024 Equity Incentive Plan. Artiva’s disclosures identify AlloNK as an off-the-shelf NK cell therapy candidate used with anti-CD20 monoclonal antibodies in autoimmune-disease trials, alongside standard public-company capital-structure and securities information.
ARTV submitted a Rule 144 notice to sell 28,000 shares of Common Stock consisting of restricted stock units that vested under a registered plan on 05/15/2026. The filing lists transaction-related figures including 258,160 and 48,588,198 alongside the 05/18/2026 filing/processing date.
The RSUs are described as compensation for services rendered to the issuer. The filing names Morgan Stanley Smith Barney LLC as the broker and identifies Nasdaq as the trading venue.
Artiva Biotherapeutics disclosure: Viking Global Investors and affiliated entities report beneficial ownership of 2,604,166 shares of Common Stock, representing 5.4% of the class based on 48,588,198 shares outstanding following the issuer's underwritten offering that closed on May 11, 2026. The disclosed stake consists of 1,822,916 shares held by Viking Global Opportunities entities and 781,250 shares held by Viking Global Opportunities Vintage IV entities; voting and disposition authority is shared across the reporting entities and two named individuals.
RA Capital Management and affiliated funds report a 33.7% beneficial stake in Artiva Biotherapeutics, Inc. They disclose ownership of 16,377,468 shares of common stock through several vehicles, including RA Capital Healthcare Fund, Nexus funds, a managed account and stock options.
On May 11, 2026, RA Capital Healthcare Fund bought 6,510,416 common shares at $11.52 per share and Pre-Funded Warrants for 2,170,138 shares at $11.5199 per warrant share, for a total of $99,999,765.07. The Pre-Funded Warrants are exercisable at $0.0001 per share but include a 9.99% beneficial ownership blocker. The filing also notes 13,750 stock options vesting on June 24, 2026 at a $1.61 exercise price.
Artiva Biotherapeutics received a large indirect equity investment from RA Capital–affiliated entities. On May 11, 2026, RA Capital–managed vehicles reported open‑market purchases of 6,510,416 shares of Artiva common stock at $11.52 per share and 2,170,138 Pre-Funded Warrants at $11.5199 per warrant.
Following these trades, the reporting entities indirectly held 15,203,995 shares of common stock and 2,170,138 Pre-Funded Warrants, along with additional indirect common stock positions of 68,320, 826,832, and 264,571 shares through various RA Capital funds and a separately managed account.
The filing states that RA Capital Management, its general partner, and principals disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest. The Pre-Funded Warrants are exercisable immediately, but the Fund cannot exercise them if doing so would push its beneficial ownership above 9.99% of Artiva’s outstanding common stock.
Artiva Biotherapeutics, Inc. entered into an underwriting agreement to sell 23,871,526 shares of common stock at $11.52 per share and pre-funded warrants to purchase 2,170,138 shares at $11.5199 per warrant. The company expects gross proceeds of approximately $300.0 million from this offering.
The transaction is being conducted under an effective Form S-3 shelf registration, with closing expected on May 11, 2026, subject to customary conditions. The pre-funded warrants are exercisable at any time, subject to beneficial ownership limits generally set at 4.99% or 9.99%, adjustable up to 19.99% with 61 days’ prior notice.
Artiva Biotherapeutics is offering 23,871,526 shares of common stock and pre-funded warrants to purchase up to 2,170,138 shares. The public offering price is $11.52 per share (pre-funded warrants priced at $11.5199), generating aggregate gross proceeds of approximately $299,999,752.27 and expected net proceeds to the company of about $280.5 million. The prospectus supplement summarizes clinical progress for AlloNK, including positive initial autoimmune data and FDA alignment on a planned Phase 3 registrational trial in refractory rheumatoid arthritis.
Artiva Biotherapeutics reported a net loss of $23.5 million (basic and diluted loss of $0.95 per share) for the quarter ended March 31 2026, reflecting continued investment in its NK cell therapy pipeline.
Research and development expenses rose to $19.3 million, driven mainly by clinical work on lead candidate AlloNK, while general and administrative costs were stable at $5.1 million. Net cash used in operating activities was $21.0 million.
The company ended the quarter with $86.8 million in cash, cash equivalents and short-term investments and an accumulated deficit of $354.1 million. Management believes this cash runway funds planned operations into the second quarter of 2027 as Artiva advances AlloNK toward a planned Phase 3 trial in refractory rheumatoid arthritis.
Artiva Biotherapeutics reported a first-quarter 2026 net loss of $23.5 million as it advances its AlloNK cell therapy program for autoimmune diseases. Cash, cash equivalents and investments were $86.8 million as of March 31, 2026, down from $108.0 million at year-end 2025.
Initial refractory rheumatoid arthritis data from AlloNK plus rituximab showed a 71% ACR50 response rate at six months in a company-sponsored Phase 2a basket trial, with no patients relapsing or needing new immunomodulatory drugs. Across 55 autoimmune patients, no cytokine release syndrome or ICANS and a 2% rate of grade 3 or higher infections were reported.
The company has alignment with the FDA on conducting a single Phase 3 registrational randomized controlled trial in approximately 150 refractory RA patients, comparing AlloNK plus rituximab to rituximab alone, with ACR50 at six months as the primary endpoint. Trial initiation is planned for the second half of 2026 and a potential BLA submission is targeted for 2029.
Artiva Biotherapeutics, Inc. filed Amendment No. 1 to its annual report for the year ended December 31, 2025 to add Part III information on directors, executive officers, governance, compensation and ownership.
The company describes an eight‑member classified board, key board committees and an amended Code of Business Conduct and Ethics and Insider Trading Policy. It details 2025 pay for named executives, including total compensation of $6,671,215 for CEO Fred Aslan, $1,536,715 for COO/Chief Legal Officer Jennifer Bush, and $1,415,855 for Chief Technical Operations Officer Christopher Horan.
The filing explains 2025 and early‑2026 RSU grants, an option‑for‑RSU exchange, and change‑in‑control severance protections. It also presents director retainers and option grants, and lists major shareholders, with RA Capital–affiliated funds reported at 39.9% of common stock and GC Corp–affiliated entities at 18.5% as of March 31, 2026. Shares outstanding were 24,716,672 as of February 27, 2026.
Huston Thad Allen reported acquisition or exercise transactions in this Form 4 filing.
Artiva Biotherapeutics’ Chief Financial Officer, Thad Allen Huston, received an equity award of 220,000 shares of common stock on March 10, 2026. The Form 4 describes this as a restricted stock unit grant under the company’s 2025 Inducement Plan, with no cash purchase price and resulting direct ownership of 220,000 shares.